It was known that the common endocrine treatment for non-metastatic breast cancer relies on the expression of ERα (Waks and Winer, 2019), and our results demonstrated that loss of Frmd8 promotes mammary tumor growth and confers tamoxifen resistance in mice. Here, FRMD8 is linked to breast carcinoma.